Short-Term Effectiveness of Ultrasound-Guided Corticosteroid Hydrodissection
NCT ID: NCT04848324
Last Updated: 2021-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
28 participants
INTERVENTIONAL
2018-12-01
2020-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods: A prospective cohort of patients with CTS were retrospectively evaluated. 28 patients were selected randomly who received ultrasound (US)-guided triamcinolone hydrodissection (3 mL) as intervention group and received US-guided triamcinolone injection (1 mL) as control group, from the data (case-control ratio 1:1). Outcome measures were the Boston Carpal Tunnel Questionnaire (BCTQ), hand grip strength (HGS), fhe cross-sectional area (CSA) of the median nerve and Short Form 12 (SF-12). Assessments were recorded at baseline, 1 and 4 weeks after injection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ultrasound-Guided Injection vs Intramuscular Steroid for Carpal Tunnel Syndrome
NCT06725420
Efficacy of Ultrasound-Guided Hydrodissection in Carpal Tunnel Syndrome
NCT05222126
Comparison of Injection Techniques in Carpal Tunnel Syndrome
NCT07105540
Comparing Efficacies of Median Nerve Hydrodissection With Dexamethasone and Dextrose in Carpal Tunnel Syndrome
NCT06400433
Efficacy of Corticosteroid Injection and Nerve Hydrodissection in Carpal Tunnel Syndrome
NCT06882603
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim: To determine whether hydrodissection would provide an additional clinical effect when used along with a corticosteroid in the short term.
Methods: A prospective cohort of patients with CTS were retrospectively evaluated. 28 patients were selected randomly who received ultrasound (US)-guided triamcinolone hydrodissection (3 mL) as intervention group and received US-guided triamcinolone injection (1 mL) as control group, from the data (case-control ratio 1:1). Outcome measures were the Boston Carpal Tunnel Questionnaire (BCTQ), hand grip strength (HGS), fhe cross-sectional area (CSA) of the median nerve and Short Form 12 (SF-12). Assessments were recorded at baseline, 1 and 4 weeks after injection.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
14 patients (14 hands) who received US-guided corticosteroid hydrodissection
Corticosteroid Hydrodissection
The median nerve was examined by US at the scaphoid-pisiform level of the inlet of carpal tunnel. The hydrodissection was achieved by a total volume of 3 mL (1 mL of triamcinolone and 2 mL of saline) in the intervention group based on a study identifying median nerve hydrodissection with this volume. Half of the total volume (1.5 mL ) was delivered via the in-plane ulnar approach and the other half (1.5 mL) via the in-plane median approach to create a fluid plane along the nerve.
Control group
14 patients (14 hands) who received US-guided corticosteroid injection
Corticosteroid Injection
1 mL of triamcinolone was delivered via the in-plane ulnar approach
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Corticosteroid Hydrodissection
The median nerve was examined by US at the scaphoid-pisiform level of the inlet of carpal tunnel. The hydrodissection was achieved by a total volume of 3 mL (1 mL of triamcinolone and 2 mL of saline) in the intervention group based on a study identifying median nerve hydrodissection with this volume. Half of the total volume (1.5 mL ) was delivered via the in-plane ulnar approach and the other half (1.5 mL) via the in-plane median approach to create a fluid plane along the nerve.
Corticosteroid Injection
1 mL of triamcinolone was delivered via the in-plane ulnar approach
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. clinically diagnosed with CTS
3. electrophysiologically confirmed mild-to-moderate CTS
4. having typical CTS symptoms for at least 3 months
5. not benefiting from splinting and resting.
Exclusion Criteria
2. surgery history for CTS
3. presence of metabolic, endocrine and neoplastic disorders
4. presence of other neurological disorders (such as plexopathy, cervical radiculopathy, proximal median or ulnar neuropathy, polyneuropathy and mononeuritis multiplex)
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yasin Demir
Physical Medicine and Rehabilitation Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Merve Orucu Atar
Role: PRINCIPAL_INVESTIGATOR
Gaziler Physical Medicine and Rehabilitation, Training and Research Hospital, Department of PMR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Merve Orucu Atar
Ankara, Cankaya, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.